New onset severe ulcerative colitis following Ixekizumab therapy

Alina Mihaela Morosanu, Ioana Ruxandra Mihai, Ioana Irina Rezus, Otilia Gavrilescu, Mihaela Dranga, Cristina Cijevschi Prelipcean, Catalina Mihai


Ixekizumab is one of the three biologic agents including Secukinumab and Brodalumab that targets the Interleukin-17 (IL-17) pathway to reduce inflammation in psoriasis and ankylosing spondylitis. In this report we present the case of 42-year-old woman, who was diagnosed with psoriasis and psoriatic arthritis. One week after first administration of Ixekizumab, she developed diffuse abdominal pain, bloody diarrhea (7-8 stools/day) and fever. Following imaging (colonoscopy, computed tomography) and laboratory investigations, she was diagnosed with acute severe ulcerative colitis complicated with toxic megacolon. The medical treatment (first corticotherapy, then infliximab) has failed and the patient needed emergency colectomy. Based on the immunological mechanisms and the observation from other studies, Ixekizumab should be considered an etiology for new-onset inflammatory bowel disease.


Ixekizumab; psoriasis; ulcerative colitis; toxic megacolon; colectomy

Full Text:



Frieder J, Kivelevitch D, Haugh I, Watson I, Menter A. Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions. Clin Pharmacol Ther. 2018; 103(1):88-101. doi: 10.1002/cpt.893.

Fieldhouse KA, Ukaibe S, Crowley EL, Khanna R, O'Toole A, Gooderham MJ. Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors. Drugs Context. 2020; 9:2020-2-1. doi: 10.7573/dic.2020-2-1.

Raychaudhuri, S.K., Raychaudhuri, S.P. IL-17 and Its Receptor System: a New Target for Psoriatic Arthritis. Curr Treat Options in Rheum. 2015; 1:210-220.

Vlachos C, Gaitanis G, Katsanos KH, et al. Psoriasis and inflammatory bowel disease: links and risks. Psoriasis. 2016; 6(1):73-92. doi: 10.2147/PTT.S85194.

Gálvez J. Role of Th17 cells in the pathogenesis of human IBD. ISRN Inflamm. 2014; 2014:1-14. doi: 10.1155/2014/928461.

Puig L. Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, Secukinumab, ixekizumab, and others. Curr Probl Dermatol. 2018; 53:49-63. doi: 10.1159/000479475.

Fauny M, Moulin D, D'Amico F, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis. 2020; 79(9):1132-1138. doi: 10.1136/annrheumdis-2020-217927.

Whibley N, Gaffen SL. Gut-Busters: IL-17 Ain’t Afraid of No IL-23. Immunity. 2015; 43:620-622. doi: 10.1016/j.immuni.2015.10.001.

Hueber W, Sands BE, Lewitzky S, et al. Secukinumab in Crohn's Disease Study Group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012; 61(12):1693-1700. doi: 10.1136/gutjnl-2011-301668.

Nehring P, Przybyłkowsk A. Is Psoriasis Treatment a Risk Factor for Inflammatory Bowel Disease?. Pharmaceutical Medicine. 2020; 34(1):257-262. doi: 10.1007/s40290-020-00340-1.

Egeberg A, Mallbris L, Warren RB, et al. Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. Br J Dermatol. 2016; 175(3):487-492. doi: 10.1111/bjd.14528.

Hohenberger M, Cardwell LA, Oussedik E, Feldman SR. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat. 2018; 29(1):13-18. doi: 10.1080/09546634.2017.1329511.

Genovese MC, Mysler E, Tomita T, et al. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatology (Oxford). 2020; 59(12):3834-3844. doi: 10.1093/rheumatology/keaa189.

Philipose J, Ahmed M, Idiculla PS, Mulrooney SM, Gumaste VV. Severe de novo Ulcerative Colitis following Ixekizumab Therapy. Case Rep Gastroenterol. 2018; 12(3):617-621. doi: 10.1159/000493922.

Mu X, Fardy J, Reid S, Trahey J. Severe drug-associated colitis with Crohn's features in setting of ixekizumab therapy for chronic plaque psoriasis. BMC Gastroenterol. 2021; 21(1):361. doi: 10.1186/s12876-021-01936-w.

Yamada A, Wang J, Komaki Y, Komaki F, Micic D, Sakuraba A. Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents. Aliment Pharmacol Ther. 2019; 50(4):373-385. doi: 10.1111/apt.15397.

Reich K, Leonardi C, Langley RG, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017; 76(3):441-448. doi: 10.1016/j.jaad.2016.10.027.

Burisch J, Eigner W, Schreiber S, et al. Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis. PLoS One. 2020; 15(5):e0233781. doi: 10.1371/journal.pone.0233781.

Strober B, Leonardi C, Papp KA, et al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. J Am Acad Dermatol. 2017; 76(3):432-440. doi: 10.1016/j.jaad.2016.09.026.

Griffiths CEM, Gooderham M, Colombel JF, et al. Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure. Dermatol Ther. 2022; 12(6):1431-1446. doi: 10.1007/s13555-022-00743-9.

Penso L, Bergqvist C, Meyer A, et al. Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System. Arthritis Rheumatol. 2022; 74(2):244-252. doi: 10.1002/art.41923.

Wright S, Alloo A, Strunk A, Garg A. Real-world risk of new-onset inflammatory bowel disease among patients with psoriasis exposed to interleukin 17 inhibitors. J Am Acad Dermatol. 2020; 83(2):382-387. doi: 10.1016/j.jaad.2020.04.010.

Fauny M, D'Amico F, Bonovas S, et al. Faecal Calprotectin for the Diagnosis of Bowel Inflammation in Patients With Rheumatological Diseases: A Systematic Review. J Crohns Colitis. 2020; 14(5):688-693. doi: 10.1093/ecco-jcc/jjz205.


Copyright (c) 2022 Alina Mihaela Morosanu, Ioana Ruxandra Mihai, Ioana Irina Rezus, Otilia Gavrilescu, Mihaela Dranga, Cristina Cijevschi Prelipcean, Catalina Mihai

Creative Commons License
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


ISSN: 2360-6975